Research Summary
My research falls into two overlapping areas: (i) industrial organization and competition economics (mostly
applied to the health sector. i.e., hospitals, pharmaceuticals, etc. but not exclusively), and (ii) health outcomes and health policies. The latter also spill into issues of education, gender, and racial equity.
Some of my recent work in pharmaceuticals focuses on firm strategies and how they impact consumer welfare, firm profits, and growth. I have worked on the valuation/welfare effects of introducing generics and second-generation (`me-too') drugs in a product market, the impact of additional presentations on the growth of a business unit, and now more recently on entry deterring effects of presentation proliferation and of product hopping. I have also worked on pay-for-delay deals in the European and American legal contexts and the cost of such (anticompetitive) deals. One of the main contributions of this work is the policy simulations that show which legislative changes are likely to make anti-competitive deals not possible and which might make the situation worse.
Concurrently, I am also working on policies to address the rise of antibacterial resistance via managing the demand for broad- vs narrow-spectrum antibiotics. I also have current work on evaluating alcohol regulations such as a ban on non-linear pricing or establishing price floors to curb excessive alcohol consumption and its heterogenous impact.
Working papers/work in progress
- "Lockdown Drinking: The Sobering Effect of Alcohol Minimum Pricing" (with Ratula Chakraborty, Paul W. Dobson and Marcello Marciano). 2021. R&R at Economic Inquiry. (Download latest wp-version from here.)
- "Antibiotic consumption in the UK and the cost of shifting demand away from broad-spectrum drugs" (with Franco Mariuzzo and Weijie Yan). CCP Working Paper 19-3. R&R at International Journal of IndustrialOrganization. (Download latest wp-version from here.)
- "Banning volume discounts to curb excessive consumption: A cautionary tale" (with Paul Dobson, Marcello Morciano, and Marc Suhrcke). September 2021. R&R at European Economic Review. (Download latest wp-version from here.)
- "Do the poor pay disproportionately more for increasing market concentration? A study of retail petroleum markets" (with Sean Ennis, Franco Mariuzzo, and Peter Ormosi). March 2022. R&R at Journal of Industrial Economics. (Download latest wp-version from here.)
- "Proliferation and entry deterrence" (with Weijie Yan). CCP Working Paper 20-04. (former title: "Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market") (Download latest wp-version from here.)
- "Merger review using online experiments'' (Stefan Penczynski and Janithe Siriwardana). In preparation. (Download latest slides from here.)
- "Estimating demand for zero priced products and the value of personal data" (with Michael Kummer). In preparation. (Download latest slides from here.)
- "Discrimination in healthcare: A field experiment with Pakistan's Transgender community" (with Husnain F. Ahmad and Sheheryar Banuri). August 2021. (Download latest wp-version from here.)
Publications
- "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions" (with Franco Mariuzzo and Ann Rita Bennato). Small Business Economics, 57(1) 603-634. 2021. (Download last wp-version from here.)
- "Entry limiting agreements for pharmaceuticals: pay-to-delay and authorized generic deals'' (with Franco Mariuzzo and Arnold Polanski). Journal of Economics and Management Strategy, 29(3) 516-542, Fall 2020. (Download last wp-version from here.)
- "Demand estimation and merger simulations for drugs: Logits v. AIDS" (with Franco Mariuzzo). International Journal of Industrial Organization, 61 (November), 653-685, 2018. (Download last wp-version from here.)
- Can drug price hikes via debranding be prevented?" (with Bruce Lyons). Prescriber, 28(4), 44-46, April, 2017. (Download last wp-version from here.)
- "Selective admission into stroke unit and patient outcomes: a tale of four cities" (with I Wellwood, A Rudd, P Langhorne, M
Dennis and CWolfe). Health Economics Review,
4(1), 1-10, 2013. (Download last wp-version from here.)
- "What is the price of pay-to-delay deals?" Journal of Competition Law and Economics,
9(3), 739-753, 2013. (Download last wp-version from here.)
- "Entry in the ADHD drugs market: Welfare impact of generics and me-toos" (with Gary Fournier). Journal of Industrial Economics, 61(2), 339-392, 2013. (Download last wp-version from here.)
- "School accountability laws and consumption of psychostimulants" (with Helen Schneider). Journal of Health Economics, 30(2), 355-372, 2011. (Download last wp-version from here.)
- "Managed care and the adoption of technology: The case of cardiac catheterization". International Journal of Industrial Organization, 27(2), 223-237, March, 2009. (Download last wp-version from here.)
- "Risk factors for discontinuing drug therapy among children with ADHD" (with Frank Heiland, Peter Levine and Tom Ray). Health Services and Outcomes Research Methodology, 8(3), 134-158, September, 2008. (Download last wp-version from here.)
- "Open versus closed firms and the dynamics of industry evolution" (with Ashish Arora). Journal of Industrial Economics, 55(3) 499-527, September, 2007. (Download last wp-version from here.)
- "Government health expenditures and health outcomes" (with Yunwei Gai and Pablo Gottret). Health
Economics, 16(3),257-273, March, 2007. (Download last wp-version from here.)
- "Attention-deficit/hyperactivity disorder in children: Excess costs before and after initial diagnosis and treatment" (with Tom Ray, Peter Levine, Lisa Croen, Teh-wei Hu and Laurel Habel). Archives of Pediatrics & Adolescent Medicine, 160(10), 1063-1069, 2006.
- "An analysis of the significant variation in psychostimulant use across the U.S." (with Rick Mayes and Richard Scheffler). Journal of Pharmacoepidemiology and Drug Safety, 14(4), 267-275,
2005.
Reports and Chapters
- "Assessing the impact of health care expenditures on mortality using cross-country data" (with Ryota Nakamura, James Lomas, Karl Claxton, Rodrigo Moreno-Serra, and Marc Suhrcke) in Global Health Economics: Shaping Health Policy In Low- And Middle-income Countries 2020. World Scientific Publishing Co. Ltd, pp.3-49. (Download last wp-version from here.)
- "Evaluating wholesale and retail mergers in pharmaceuticals" (with Franco Mariuzzo). OECD's Global Forum on Competition, DAF/COMP/GF(2014)4, February, 2014. (Download last wp-version from here.)
- "Improving health outcomes" (with Yunwei Gai and Pablo Gottret) in Health Financing Revisited: A Practitioner's Guide by Pablo Gottret and George Schieber. World Bank, Washington, D.C., 2006. (Download last wp-version from here.)
Retired papers
This page
was last updated on Aug/18/2022